Wells Fargo’s Bicycle Therapeutics BCYC Stock Holding History

Wells Fargo’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$848	Hold	200	–	–	﹤0.01%	6471
2026 Q1	$928	Hold	200	–	–	﹤0.01%	6343
2025 Q4	$1.42K	Hold	200	–	–	﹤0.01%	6260
2025 Q3	$1.55K	Hold	200	–	–	﹤0.01%	6216
2025 Q2	$1.39K	Buy	+200	New	+$1.59K	﹤0.01%	6266
2024 Q4	–	Sell	-30	Closed	-$679	–	7061
2024 Q3	$679	Buy	+30	New	+$692	﹤0.01%	6149
2023 Q4	–	Sell	-12	Closed	-$241	–	7593
2023 Q3	$241	Buy	+12	New	+$274	﹤0.01%	6538
2023 Q2	–	Sell	-19	Closed	-$404	–	7583
2023 Q1	$404	Buy	+19	New	+$477	﹤0.01%	6609
2022 Q3	–	Sell	-1	Closed	–	–	6655
2022 Q2	$0	Buy	+1	New	+$21	﹤0.01%	6796
2022 Q1	–	Sell	-6,001	Closed	-$365K	–	7054
2021 Q4	$365K	Sell	6,001 -103	-2%	-$5.68K	﹤0.01%	4914
2021 Q3	$254K	Buy	+6,104	New	+$213K	﹤0.01%	4996

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GSK plc London $602M AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Wells Fargo's BCYC Position: Q2 2026 in Review

Wells Fargo held its Bicycle Therapeutics (BCYC) position steady in Q2 2026 at 200 shares worth $848. The position accounts for ﹤0.01% of the portfolio, ranked #6471.

Wells Fargo first reported a position in BCYC in Q3 2021 and has held it in 11 quarters since. The position peaked at $365K in Q4 2021. 103 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

Wells Fargo held 200 shares of Bicycle Therapeutics worth $848 as of Q2 2026.
Wells Fargo left its Bicycle Therapeutics share count unchanged in Q2 2026.
Bicycle Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6471 holding.
Wells Fargo first reported a position in Bicycle Therapeutics in Q3 2021 and has held it in 11 quarters since.
Wells Fargo's Bicycle Therapeutics position peaked at $365K in Q4 2021.
103 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.